MARKET

CTMX

CTMX

CytomX
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.26
-0.18
-3.31%
After Hours: 5.15 -0.11 -2.09% 16:53 09/24 EDT
OPEN
5.39
PREV CLOSE
5.44
HIGH
5.45
LOW
5.23
VOLUME
382.97K
TURNOVER
--
52 WEEK HIGH
10.05
52 WEEK LOW
4.280
MARKET CAP
342.73M
P/E (TTM)
-4.4396
1D
5D
1M
3M
1Y
5Y
CytomX Therapeutics Announces New Employment Inducement Grants
CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage, oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated therapeutics based on its Probody(R) technology platform, today announced that on Sep...
GlobeNewswire · 09/16 12:00
CytomX Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conference
CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated therapeutics based on its Probody technology platform, today announced that Sean McCar...
GlobeNewswire · 09/07 12:00
Return on Capital Employed Overview: CytomX Therapeutics
After pulling data from Benzinga Pro it seems like during Q2, CytomX Therapeutics (NASDAQ:CTMX) brought in sales totaling $16.29 million. However, earnings decreased 22.9%, resulting in a loss of $19.20 million.
Benzinga · 08/27 21:14
The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17)
Benzinga · 08/18 11:37
Insider Trends: Insider at CytomX Therapeutics Reports Option Conversion Amid 90-Day Selling Trend
MT Newswires · 08/13 17:33
The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 12)
Benzinga · 08/13 11:43
The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 11)
Benzinga · 08/12 12:09
Stocks That Hit 52-Week Lows On Tuesday
    Before 10 a.m. ET on Tuesday, 60 companies set new 52-week lows.
Benzinga · 08/10 14:05
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CTMX. Analyze the recent business situations of CytomX through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CTMX stock price target is 13.14 with a high estimate of 18.00 and a low estimate of 7.00.
EPS
Institutional Holdings
Institutions: 189
Institutional Holdings: 59.62M
% Owned: 91.50%
Shares Outstanding: 65.16M
TypeInstitutionsShares
Increased
56
9.95M
New
14
2.74M
Decreased
35
4.11M
Sold Out
17
6.48M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.13%
Pharmaceuticals & Medical Research
-1.02%
Key Executives
Chairman/President/Chief Executive Officer/Director
Sean McCarthy
Chief Financial Officer/Senior Vice President
Carlos Campoy
Executive Vice President
Amy Peterson
Senior Vice President/Chief Compliance Officer/General Counsel/Secretary
Lloyd Rowland
Senior Vice President
Alison Hannah
Lead Director/Independent Director
Matthew Young
Independent Director
Halley Gilbert
Independent Director
Frederick Gluck
Independent Director
Elaine Jones
Independent Director
James Meyers
Independent Director
Mani Mohindru
Independent Director
John Scarlett
No Data
About CTMX
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies. Its product candidates include CX-072, CX-2009, CX-2029, Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and CX-188. Its Probody platform utilizes active proteases in tumor tissue to allow monoclonal antibody-based therapies. Its investigational Probody therapeutics address clinically validated cancer targets in immuno-oncology, such as programmed death-ligand 1, against which CX-072 is directed, as well as targets, such as cluster of differentiation 166, against, which CX-2009 is directed.

Webull offers kinds of CytomX Therapeutics Inc stock information, including NASDAQ:CTMX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CTMX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CTMX stock methods without spending real money on the virtual paper trading platform.